Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 201

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 201
---
 product candidates could be delayed or prevented. Kineta’s future growth depends, in part, on its ability to penetrate multiple markets in which Kineta would be subject to additional regulatory burdens and other risks and uncertainties. Kineta’s future profitability will depend, in part, on its ability to commercialize its product candidates, if approved, in markets in the United States, Europe, the UK and other countries where Kineta maintains commercialization rights. As Kineta begins to commercialize its product candidates, if approved, in multiple markets, Kineta is subject to additional risks and uncertainties, including:

| • |     | foreign currency exchange rate fluctuations and currency controls; |

| • |     | economic weakness, including inflation, or political instability in particular economies and markets; |

| • |     | potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or               
 due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; |

123

| • |     | the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of 
 which vary between countries;                                                                                 |

| • |     | different medical practices and customs in multiple countries affecting acceptance of drugs in the marketplace; |

| • |     | differing payor reimbursement regimes, governmental payors or patient 
 self-pay systems and price controls;                                  |

| • |     | tariffs, trade barriers, import or export licensing requirements or other restrictive actions; |

| • |     | compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; |

| • |     | workforce uncertainty in countries where labor unrest is common; |

| • |     | reduced or loss of protection of intellectual property rights in some foreign countries, and related prevalence 
 of generic alternatives to therapeutics; and                                                                    |

| • |     | becoming subject to the different, complex and changing laws, regulations and court systems of multiple 
 jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations.             |

These and other risks associated with international operations may adversely affect Kineta’s ability to attain or maintain profitable operations. Future sales of Kineta’s products or its product candidates, if they are approved, will be dependent on purchasing decisions of and reimbursement from government health administration authorities, distributors and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including disruptions due to political instability or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or